Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Buy" from Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) have been assigned a consensus rating of "Buy" from the five brokerages that are covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $36.20.

Several equities research analysts recently issued reports on the stock. Wedbush reaffirmed an "outperform" rating and set a $27.00 price target on shares of Pharvaris in a research note on Thursday, June 5th. Cantor Fitzgerald cut their price target on Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. Finally, Guggenheim started coverage on Pharvaris in a research note on Wednesday, June 11th. They set a "buy" rating and a $32.00 price objective for the company.

Pharvaris Trading Up 5.3%

Shares of PHVS opened at $18.76 on Friday. Pharvaris has a twelve month low of $11.51 and a twelve month high of $25.50. The firm has a market capitalization of $980.96 million, a P/E ratio of -6.23 and a beta of -2.82. The stock's fifty day simple moving average is $17.06 and its 200 day simple moving average is $16.66.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.09). Sell-side analysts predict that Pharvaris will post -2.71 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in PHVS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Pharvaris by 30.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company's stock worth $1,222,000 after purchasing an additional 14,838 shares during the last quarter. Deutsche Bank AG lifted its position in shares of Pharvaris by 13.0% in the 4th quarter. Deutsche Bank AG now owns 18,168 shares of the company's stock worth $348,000 after buying an additional 2,087 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Pharvaris by 205,286.7% in the 4th quarter. Bank of America Corp DE now owns 30,808 shares of the company's stock valued at $591,000 after buying an additional 30,793 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after buying an additional 2,847 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Pharvaris by 11.2% during the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock valued at $189,000 after buying an additional 994 shares during the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.